In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Diabetes Assays are tests to first diagnose diabetes and assess the risk of diabetes, such as pre-diabetes, through analysis of blood. GlobalData uses proprietary data and analytics to provide a comprehensive report on the diabetes assays devices market, including market shares of different players within Russia. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the diabetes assays market in Russia was Siemens followed by Abbott Laboratories, F. Hoffmann-La Roche, Bio-Rad Laboratories, Danaher, Quidelortho, EKF Diagnostics, Sinocare and DiaSorin.
The Diabetes Assays market comprises C-Peptide Assay, Glycated Hemoglobin (HbAc) Lab Assay, Glycated Hemoglobin (HbAc) Point of care (POC) Assay, Insulin Assay, and Fasting Glucose Assay
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the diabetes assays devices market within Russia was expected to be over $10m in 2022.
For the latest complete market share analysis of diabetes assays device market in Russia, buy the report here.